knowledge -WSS

knowledge

author：entertainment 2025-09-03 12:05:13 - browse：37217

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Food makers tried to stack nutrition panel with preferred experts

Wikipedia

WSS

IRA could hurt research into orphan drugs for rare diseases

How medical schools plan to diversify without affirmative action

FDA panel endorses Alnylam’s heart drug — after picking it apart

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Walmart eyes Medicare Advantage provider ChenMed

Telehealth for opioid use disorder is lifesaving

focus

knowledge

entertainment

At least 13 dead in Texas as scorching temps continue

Walmart eyes Medicare Advantage provider ChenMed

Cancer drug shortages should be causing more outrage

What to make of Biden’s latest efforts on cancer research

Hollywood unions extend contract negotiations for actors

Medicare Advantage insurers face 0.2% cut to 2025 payments

Jerome Adams on the need for new antivirals for Covid

FDA panel endorses Alnylam’s heart drug — after picking it apart

How one medical school became remarkably diverse

How medical schools plan to diversify without affirmative action

focus

White House touts steps to stem shortages of cancer treatments

Will the IRA bring competition to the biologics market?

Long Covid needs a new name — and a new frame

Humana’s losses in Medicare Advantage tank its stock

Syphilis numbers in the United States reach record heights

Generate Biomedicines machine learning biotech raises $273M

Wikipedia

Wikipedia

entertainment

leisure time